Fulgent Genetics (FLGT) Change in Receivables (2015 - 2026)

Fulgent Genetics has disclosed Change in Receivables across 12 years of filings, most recently posting -$16.4 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$16.4 million, down 463.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (down 89.71% YoY), and the FY2025 annual result was $23.3 million, up 42.62% from the prior year.
• Change in Receivables came in at -$16.4 million for Q1 2026 at Fulgent Genetics, down from $15.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $32.9 million in Q1 2022 to a low of -$44.4 million in Q4 2022.
• The 5-year median for Change in Receivables is $1.6 million (2024), against an average of -$2.8 million.
• Across the five-year window, Change in Receivables surged 404.85% in 2025 and slumped 463.2% in 2026, its largest moves.
• Fulgent Genetics' Change in Receivables stood at -$44.4 million in 2022, then jumped by 111.72% to $5.2 million in 2023, then soared by 155.86% to $13.3 million in 2024, then grew by 15.4% to $15.4 million in 2025, then plunged by 206.85% to -$16.4 million in 2026.
• The last three Change in Receivables figures came in at -$16.4 million (Q1 2026), $15.4 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.